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F
oot ulcers in patients with diabetes
lead to infections, amputations, and
high costs, and their prevention is a
stated goal of the American Diabetes
Association. To assess the beneﬁts of
various interventions on the prevention
of future diabetic foot ulcers, we searched
for and reviewed all randomized clinical
trials(RCTs)onthepreventionofdiabetic
foot ulcers and evaluated their efﬁcacy
and scientiﬁc validity on the basis of an
established systemic grading system.
Only 13 RCTs were identiﬁed. All in-
volved secondarypreventionoramixture
of primary and secondary prevention.
Most were small and of poor quality,
with negative studies generally being of
better quality than positive studies. Of all
methods proposed to prevent diabetic
foot ulcers, only foot temperature-guided
avoidancetherapywasfoundbeneﬁcialin
RCTs, although this needs to be validated
in other populations. These observations
only apply to high-risk populations, and
the beneﬁts to the general population
with diabetes are unclear.
Introduction
Diabetic foot ulcers are the cause of
immense suffering and health system
costs (1). The lifetime risk of a person
with diabetes developing a foot ulcer
may be as high as 25%, whereas the an-
nual incidence of foot ulcers is as high as
2%(2–6).Multiplecomponentcauses,in-
cluding peripheral neuropathy, peripheral
vascular disease (PVD), foot deformity,
and smoking, interact in the causal path-
way to foot ulceration. In several cross-
sectional and retrospective studies, the
prevalenceofPVDandperipheralneurop-
athy in patients was found to be as high as
40%. However, no prospective study
clearly documented their relative contri-
bution.Thisreviewisconcernedprimarily
with clinical trials on the prevention of
foot ulcers in the neuropathic, or insen-
sate, foot.
Several physiologic measurements of
the presence and degree of peripheral
neuropathy have been shown to be pre-
dictive of the risk of future foot ulcer in
diabetic patients (2), including 1)s e n s a -
tiontothe5.07(10g)Semmes-Weinstein
(SWM) monoﬁlament, 2) vibration per-
ceptionthreshold,3)sensationtothetun-
ing fork, and 4) formal nerve conduction
studies. However, despite the ability to
predict the risk of future occurrence of
foot ulcers via the development of neu-
ropathy, once neuropathy has developed,
the prevention of foot ulcers remains a
challenge. Indeed, although the graded
SWM is widely used in practice to diag-
nose or screen for neuropathy, to docu-
ment insensate feet, and to predict foot
ulcers, repeated further testing with the
SWM does not yield any useful informa-
tion. Therefore, most patients with insen-
sitive feet are referred for “preventive
podiatry care” and specialized shoes, but no
attempt is made to target more aggressive
prevention in those highest risk individ-
uals. It would be extremely valuable to
be able to further stratify and predict the
risk of a foot ulcer in the insensate
foot (lost SWM perception) and devise
methods of preventing future ulcer oc-
currence.
The goal of this review is to system-
atically assess RCTs regarding possible
methods to prevent diabetic foot ulcers.
This review does not evaluate articles on
methods to simply predict the likelihood
of future ulcers or on treatment ap-
proaches to pre-existing foot ulcers.
Research design and methods
A search was made for RCTs that de-
scribed or reviewed methods to prevent
the outcome of diabetic foot ulcers as the
primary outcome in subjects deemed at
risk. In addition, relevant references cited
in these articles and in identiﬁed review
articles were also reviewed. Both primary
prevention and secondary prevention
(subjects with a history of previous foot
ulcers) were considered. Medline and
PubMed were screened for relevant arti-
cles published between 1 January 1960
and 30 April 2010, using the combina-
tion of the terms “diabetes,”“ foot,” and
“ulcer.” Additional searches were per-
formed with the same search terms using
theClinicalTrialssectionofthe Cochrane
Library, ClinicalTrials.gov, International
Clinical Trials Registry Platform registry,
and the Google databases. Unpublished
registered studies were considered if
study design, results, and validity criteria
could be ascertained. Nonrandomized
trials, prospective observational studies,
and case-control studies were excluded
from this review. The initial search was
conducted by Y.A. and reviewed for com-
pleteness by V.F. Subsequently, two of
theauthors(Y.A.andV.F.)independently
evaluated the articles that qualiﬁedonthe
basis of the selection criteria. The articles
were then graded on the basis of the
Amsterdam/Maastricht consensus list
(10/5/2) system as initially described by
Verhagen et al.(7) andaccepted for usein
the Cochrane commentaries system (8).
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REVIEWThis method of assessment of the quality
of studies and the risk of bias follows the
guidance in the Cochrane Handbook for
SystematicReviewsofInterventions,Version
5.0.2 (9). All the authors reviewed the ﬁ-
nalselectionand theaccuracy ofthe grad-
ing scores. The criteria for grading the
quality of clinical trials are listed in Table
1.Eachitemisgradedaspositive(+),neg-
ative (2), indeterminable (?), or not ap-
plicable (N). The ﬁnal score is the sum of
positive results. For the purpose of this
article, the scores will be reported as
(A/B/C) for absolute values for the three
groups. To score a positive mark, the evi-
dence for the speciﬁc item had to be stated
orclearlyimplied(e.g.,ifthephysicianwas
the assessor of the end point and the same
physician was stated to be blind), (A6) was
presumed positive. When two items are
listed in the criteria in Table 1, the score
is 0, 1/2, or 1 based on the number of (+).
Results
The initial PubMed search, using the
inclusive combination of the terms “dia-
betes” and “foot” and “ulcer,” yielded
2,014 articles. Each abstract (or the full
article if needed) was reviewed to deter-
mine eligibility, yielding 14 relevant re-
view articles (2,8,10–21) and 11 RCTs
(22–32) documenting the primary or sec-
ondary prevention of future foot ulcers as
an end point. One additional RCT was
found in ClinicalTrials.gov (K.R. Higgins,
L.A.Lavery,K.A.Athanasiou,D.R.Lanctot,
G.P. Costantinidis, C.M. Agrawal, and
R.G. Zamorano, personal communica-
tion). No additional articles were identi-
ﬁed via the Cochrane database or Google
search.Reviewarticleswereextractedonly
to look for original articles, and no addi-
tional articles were found. The RCT in-
cluded four studies on patient education
and intensiﬁed monitoring (22–25), three
studies on therapeutic footwear or insoles
(26,27,33),onestudyonsurgicalbonede-
bridement(28),onestudyonAchillesten-
don lengthening (ATL) (29), and three
studies on temperature-guided avoidance
therapy(30–32).Noneofthestudieswasa
trueprimarypreventionstudy.Someused
only subjects with a previous foot ulcer,
whereas others used “high-risk group”
combinations (neuropathy plus foot de-
formity, previous ulcer, or amputation).
Table2describesthescoringforthese
studies. Note that because all the studies
measured a binary variable, C2 was not
applicable. Most of the studies did not
describe a surgical or medication-base in-
tervention, so B4 was usually not applica-
ble.Also,noneofthestudieswereblinded
to the patients (A5). (These letter/number
combinations are based on Table 1.)
Enhanced patient education and care-
taker monitoring. The study by Malone
et al. (22) enrolled 203 patients who had
foot infection, ulceration, or prior ampu-
tation, excluding those requiring acute
treatment. Patients in the active group re-
ceived 1 h of education. The primary end
point was a combination of subsequent
limb amputation and recurrent ulcer or
foot infection. Follow-up was by phone,
letter, or physical evaluation. The authors
reported a reduction of new events from
28%oflimbsto10%oflimbs(noanalysis
per patient was provided) and a post hoc
reduction of ulceration from 15 to 5%.
The study was unblinded, and baseline
characteristics were not described. It was
scored as (4.5/2.5/1).
In the study by Litzelman et al. (23),
patients received “usual care” (not de-
ﬁned) or a multifaceted intervention, in-
cluding foot care education, behavior
contract, and regular reminders. The pro-
viders of the intervention group were
instructed to have patients remove their
footwear, perform foot examinations, and
provide additional foot care education.
The care providers, who also assessed the
end point, were blinded to assignment.
Many baseline characteristics were not de-
scribed (neuropathy, blood pressure,
smoking among others), and only one
third of eligible patients participated. Mul-
tiple end points (not prespeciﬁed in the
protocol) were used without statistical
penalties. Although the protocol seemed
to improve self-care and provider care,
the only signiﬁcant difference in patient
outcome (borderline, P = 0.05) was in “se-
rious foot lesions” not further speciﬁed.
The study scored (5.5/3.5/1).
The study by Lincoln et al. (24) ran-
domized 172 patients with newly healed
ulcers to receive targeted, one-on-one ed-
ucationor usualcare.Randomization was
concealed from the researcher. No differ-
ence in the subsequent incidence of foot
ulcers in 6 or 12 months was noted de-
spite better recommended foot care be-
havior in the intervention group. The
study was graded as (5.5/3.5/1).
The study by McCabe et al. (25) ran-
domized 2,001 patients into “control” and
“index”groups.However,theindexgroup
was then subdivided and reallocated mul-
tiple times on the basis of both neuropathy
and PVD, and only 127 high-risk subjects
ultimatelyattendedadiabeticfootclinic.It
is not clear what end points were prespe-
ciﬁed,howmanypatientshadneuropathy
versus PVD, whether the caretaker or as-
sessors of end point were blinded, and
what statistical methods were used. Ulti-
mately, there was a decrease in major am-
putations but not minor amputations or
ulcerations. The study scored (2/1.5/0).
Therapeutic footwear and insoles.
Uccioli et al. (26) reported a small (69
subjects) prospective multicenter random-
ized follow-up of patients with previous
foot ulceration. Patients were alternately
(not randomly) assigned to wear their
own shoes or therapeutic shoes. Baseline
characteristics were poorly described, and
caregiverswerenotblindedtoassignment.
After 1 year, there was a signiﬁcant de-
crease in recurrence of ulcers (27.7 vs.
58.3%). The study was of poor design
with a core of (3/1/1).
Reiber et al. (27) described a 2-year
RCT of 400 patients with previous full-
thicknessfootlesions(presumablyulcers)
orfootinfectionsrequiringantibioticsbut
without severe foot deformity. Patients
were randomized into three groups: two
types of insole inserts or own usual
Table 1—Clinical trial evaluation
criteria (7)
A. Ten internal validity criteria
1. Random assignment/allocation
concealed
2. Provider blinded
3. Cointervention avoided or comparable
4. Compliance acceptable
5. Patients blinded
6. Assessor of end points blinded
7. Outcome measurements relevant
8. Dropout acceptable
9. Timing of outcome measurements
comparable
10. Analysis includes intention-to-treat
analysis
B. Five descriptive criteria
1. Eligibility speciﬁed
2. Similar baselines
3. Intervention described
4. Side effects described
5. Short- and long-term measurements
described
C. Two statistical criteria
1. Sample size described
2. Point estimates and measurements of
variability presented for primary
outcome measures
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the article was unclear, and a clear opera-
tional deﬁnition was not provided. The
end point was somewhat ambiguous:
“new cutaneous erosion extending into
or through the dermis to deeper tissue or
othercutsthatdidnothealwithin30days.”
Only 400 of 763 eligible subjects
participated. Other issues were that the
study population was supposed to be
high risk, but half of the subjects did not
have neuropathy (only 58% were insen-
sate to the 5.07 monoﬁlament), probably
accounting for the low overall recurrence
rate.Caregiverswereblindtoassignment.
Patients were similar at baseline. With-
drawal from the study was 16.5%. Other-
wise, the study was well designed with a
score of (8/3/1). There were no differ-
ences in the incidence of subsequent foot
ulcerations among the three groups.
Oneadditionalstudyonfootwearwas
found in ClinicalTrials.gov. Lavery et al.
(K.R.Higgins,L.A.Lavery,K.A.Athanasiou,
D.R. Lanctot, G.P. Costantinidis, C.M.
Agrawal, and R.G. Zamorano, personal
communication) conducted a National
Institutes of Health-sponsored multicen-
ter, RCT of 299 diabetic patients with
severe neuropathy or history of previous
ulcer or amputation, comparing a shear-
reducing insole with standard therapy,
which included extra depth shoes and
vertical pressure-relieving molded insoles,
podiatrist, neuropathy assessment, dia-
betes education, and vascular assessment
(Lavery et al., personal communication,
Clinical trial reg no. NCT00499356). The
rationale for this study was based on the
previous demonstration that this unique
insole, constructed of two viscoelastic
layers, with two intervening thin sheets
of a low friction material as the middle
layer, reduced peak shear force (but not
vertical pressure) by 57%, compared with
three other similar multilayer viscoelastic
insoles that did not have the intervening
layers (33). Among those with a previous
ulcer (risk category 3), there was a relative
90% reduction in ulcers (13/38 vs. 1/40).
Thus, at least in patients with a history of
a foot ulcer, reducing shear stress in ad-
dition to standard reduction of verti-
cal forces resulted in .90% reduction
in foot ulcer recurrence. No beneﬁt
was found in patients without a previous
plantar foot ulcer. The study scored (6/
3.5/1).
Debridement. Only one randomized
study comparing surgical bony debride-
ment on the relapse of ulcers in 43
patients was found (28). The authors
claimed reduction in foot ulcers from 8
to 3 (P , 0.01). The study was small
and unblinded to both patients and the
assessors of end points. No penalty was
taken for multiple end points (total of 5).
The study received a score of (2.5/2.5/1).
Achilles tendon lengthening. Wefound
only one RCT of ATL (29), in which 64
patients with a history of forefoot ulcer
were randomized to treatment with total-
contact cast alone or to a combination
of total-contact cast with ATL. There
were two primary end points (ulcer heal-
ing and forefoot ulcer recurrence). Al-
though it is stated that the study was
randomized, approximately half the sub-
jects in the ATL group were crossed over
from the total-contact cast group before
the start of the study. Early follow-up
was via examinations. Subsequently,
monthly follow-up was via phone, and
the patients were to contact the study
coordinator if they noted a skin break-
down. No data are provided on the suc-
cessofphonecontactattempts.Long-term
veriﬁcation of events was also via phone
calls, but apparently without independent
adjudication via examination or chart re-
views. Recurrence of forefoot ulcers was
signiﬁcantly lower in the ATL group (15
vs. 59%). However, most of the effect was
seen in the few weeks after healing with
the Kaplan–Meier curves essentially paral-
lellater on,suggesting that incompletetis-
sue healing may explain the difference. In
addition, the rate of re-ulceration in the
total-cast alone was high (59%) compared
with control groups in other studies, for
example, 17% by Reiber et al. (27). Of
note, there was an increased rate of heel
ulceration in the ATL group (13 vs. 0%).
Thestudy was terminated earlybecauseof
perceived efﬁcacy, but no prespeciﬁed
stopping rules were described. No statis-
tical penalty was taken for multiple time
point observations. The study was scored
(6/5/1).
Plantar foot temperature-guided avoid-
ance therapy. Lavery et al. (30) reported
an RCT of 85 subjects at high risk for foot
ulceration (neuropathy and foot defor-
mity or a history of ulceration or partial
foot amputation). Standard therapy con-
sisted of therapeutic footwear, diabetic
foot education, and regular foot evalua-
tion by a podiatrist. Enhanced therapy
included the addition of infrared skin
thermometer to measure temperature at
six locations on the sole of the feet twice
per day. When a difference of .4°F be-
tween the same locations of the two feet
was noted, subjects were instructed to
contact the nurse and reduce activity of
the involved foot (higher temperature)
Table 2—Evaluation of studies on methods to prevent foot ulcers
Method
Internal validity criteria Descriptive criteria Stat
1 234 5 6789 1 0 1 2 3 4 5 1 2
Malone et al., 1989 E +/? — ?+— ?+++ — +? + N 2/+ + N
Litzelman et al., 1993 E +/? + ? ? — ++++ — ++ + N 2/+ + N
McCabe et al., 1998 E ?/? ? ? —— ?+ — + —— ?+N2/+ ? N
Lincoln et al., 2008 E +/? — ?+— ++++ — ++ + N 2/+ + N
Uccioli et al., 1995 F —— ??— ?+?+ — ?? ? N 2/+ + N
Reiber et al., 2002 F +/+ + ? ? — +++++ + + +— 2/+ + N
Piaggesi et al., 1998 D +/? — ??——+?+? + ? +— 2/+ + N
Mueller et al., 2003 A —/? — ??— ?+++ — ++ + — 2/+ + N
Lavery et al., 2004 T +/? + + ? — +++++ + — +N2/+ + N
Lavery et al., 2007 T +/+ + + + — ?++++ + + + N 2/+ + N
Armstrong et al., 2007 T +/+ + + ? — ?+?+? + + + N 2/+ + N
A, Achilles tendon lengthening; D, bony debridement; E, enhance education and patient monitoring; F, specialized footwear or insole; Stat, statistic criteria;
T, temperature-guided avoidance therapy.
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Arad and Associatesuntil the temperature gradient decreased
to ,4°F. During a 6-month period, new
complications were found in 20% of the
standard therapy group (seven ulcers and
twoCharcotfractures) versus 2% (one ul-
cer) in the intervention group (odds ratio
10.3,CI1.2–85.3,P=0.01).Thestudywas
single blinded (physicians). Relevant base-
line values were not well described. It is
possible that temperature monitoring led
to more intense interaction with caretakers
and thus better monitoring and therapy.
Otherwise, the study was well designed
with a score of (7.5/2.5/1).
A similar but larger study was sub-
sequently reported by the same group
(31). This was also physician blinded
and a multicenter study of 173 individu-
als at high risk for foot ulcers. Randomi-
zation was computer-generated. To
account for the possibility that effect of
temperature monitoring may be due to
more intense interaction with caregivers,
the study was divided into three groups: 1)
standardtherapy;2)structuredfootexam-
ination twice daily by the patients using a
mirror and a log book (The patient was
instructed to call the nurse if any abnor-
mality was noted.); and 3) enhanced ther-
apy group consisting of the addition of
temperature measurements to standard
therapy. If temperature increased by
4 ° Fc o m p a r e dw i t ht h ec o r r e s p o n d i n g
site on the other foot, patients were in-
structed to call the nurse and decrease
activity until the gradient decreased
to ,4°F. After 15 months, the incidence
of foot ulcer decreased from 30% in the
ﬁrsttwogroupsto8.5%intheplantarfoot
temperature-guided avoidance therapy.
The study was well conducted and scored
(8/3.5/1.5).
The study by Armstrong et al. (32)
randomized 225 patients to two groups.
Both groups received diabetic foot educa-
tion and therapeutic footwear, and daily
structured foot examinations were per-
formedasdescribedabove.Theintervention
groupalsoperformedtemperature-guided
avoidance therapy as described above,
although the patient’s physician was
blinded to the randomization compli-
ance and dropout rates were not de-
scribed. Furthermore, it is not clear
whether the analysis was based on intent
to treat. Overall incidence of subsequent
foot ulceration was lower than in other
studies (total of 8.4%). Nonetheless, the
incidence of ulcers decreased by 62%
(from 12.2 to 4.7%) in the group using
temperature monitoring. The study
scored (5/3.5/1.5).
Conclusions
It has now been 7 years since the position
statement by the American Diabetes As-
sociation on preventive foot care in di-
abetes (34). Yet the quality of the data
supportingtheusefulnessofsuchpreven-
tivecareremainspoor.Althoughthereare
many publications claiming efﬁcacy based
onretrospective studies, case-control stud-
ies, prospective observational, and non-
randomized studies, conclusions based on
such studies are often discredited by later
RCTs.
On the basis of our review, the evi-
dence for most of the interventions to
prevent a foot ulcer falls short. Clinicians
lackguidanceonwhattodoafterapatient
loses sensation. Anecdotally, many keep
testing repeatedly with a monoﬁlament,
atscheduledintervals,althoughsensation
rarely ever returns. The beneﬁto fe n -
hanced patient education or more inten-
sive caretaker involvement, specialized
footwear, surgical debridement of cal-
luses, bone resection at pressure points,
or decompression or neurolysis of the
peroneal and tibial nerves is not supported
by RCTs. The data for ATL seem enticing
at ﬁrst, in particular for prevention of
forefoot ulcers. However, a closer look
suggests that whatever beneﬁt was seen
was probably due to more complete tissue
healing during the few weeks after appar-
ent visual healing.
Thedataforplantarfoottemperature-
guided avoidance therapy are more com-
pelling. Although no large-scale clinical
trials have been reported, ;500 subjects
havebeeninvolvedtodateinthreerandom-
ized, controlled, and relatively well-
designedstudies(allfundedbytheNational
InstitutesofHealth)andthedatahavebeen
remarkably consistent, documenting a
largetreatmenteffect(62–90%relativerisk
reduction). All three studies were blinded
to the care provider who also assessed the
end points and two speciﬁed intent-to-
treat analyses; the study by Armstrong
et al. (32) presumably used the same de-
sign but did not specify intent-to-treat
analysis or describe the compliance and
dropout rates. One confounder of these
resultsisthe possibility thatusingthetem-
perature monitoring device altered pa-
tients’ behavior such that they were more
likely to examine their feet. However, it
seems that the increased contact with the
nurse in the temperature monitoring arm
was mostly triggered by ﬁndings of ele-
vated temperatures and not by visual or
tactile detection of area of concern (31).
It must also be noted that all three RCTs
of temperature-guided avoidance therapy
were performed by the same group of in-
vestigators, and this intervention has not
yet been tested by an entirely independent
groupandneedstobevalidatedinadiffer-
ent population.
Temperature monitoring could pro-
videthenextstepinthehierarchy ofsteps
to detect and prevent diabetic foot ulcer-
ations. Evaluation would start with as-
sessment of risk factors, such as severity
and duration of the disease, blood pres-
sure, lipids, poor diabetic control, smok-
ing, evidence of peripheral artery disease
and other vascular disease, weight and
mobility, and engagement in activities
that are more likely to result in injury,
such as prolonged limb use. Subjective
observation of progressive neuropathy,
with loss of sensation and neuropathic
pain, is followed by objective SWM
monoﬁlament testing. Finally, tempera-
turemeasurementseemseffectiveiniden-
tifying the subgroup of patients with
insensatefeetwhoareatriskforulceration.
When focal temperature differences .4°F
are detected, reduced use of the involved
foot,untilthetemperaturereturnedtonor-
mal (usually 2–4 days but sometimes as
long as 4 weeks), seems effective in reduc-
ing the likelihood of an ulcer.
Although the data do not support the
use of therapeutic shoes or vertical stress-
reducing insoles, shear stress-reducing
insoles seem more promising. The re-
duction from 13 ulcers to one ulcer in the
study (K.R. Higgins, L.A. Lavery, K.A.
Athanasiou,D.R.Lanctot,G.P.Costantinidis,
C.M. Agrawal, and R.G. Zamorano, per-
sonal communication) is intriguing, but
the data have not been published and a
larger RCT is clearly is needed. Further-
more, the special shear-reducing soles
were beneﬁcial only for patients who al-
ready had a foot ulcer or an amputation
(there were no events in either of the
lower-risk groups). A longer observation
period may help to detect beneﬁts in low-
riskgroups.Itisnotable,however,thatthe
observed beneﬁt was incremental to all
other traditional prevention methods (ex-
tra depth shoes and pressure-relieving
molded insoles, podiatrist, neuropathy
assessment, diabetes education, and vas-
cular assessment).
Theobservationsregardingtemperature-
guided avoidance therapy are only ap-
plicable to similar populations, that is,
high-risk diabetic patients with a history
of foot ulceration or lower-extremity am-
putation or patients with peripheral sen-
sory neuropathy with loss of protective
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Preventing foot ulcers in diabetessensation, with a foot deformity such as
hallux valgus or claw toes. They are not
applicable to primary prevention or to
patients not meeting these criteria. They
are also not applicable to patients with
severe PVD (ankle-brachial index ,0.8),
who were excluded. Temperature evalua-
tion was only tested when SWM sensation
was already lost, so data are needed re-
garding the beneﬁt of temperature mea-
surements in patients who have not yet
lost the sensation to SWM sensation.
When patients do qualify, intensive train-
ing in the proper use of the tempera-
ture measuring device and thorough
discussion to increase motivation will be
essential to ensure continuous use of the
device.
Finally, any intervention may be asso-
ciatedwithadverseeffects.Accordingtothe
Cochrane Handbook and The Adverse
Effects Methods Group, if an intervention
clearly does not work or has little potential
beneﬁt and is not widely used (such as in
the ﬁrst three methods described), it may
not be worth devoting resources toward a
detailed evaluation of adverse effects (35).
I nt h ec a s eo fA T L ,a d v e r s ee f f e c t si n -
cluded a signiﬁcant increase in incidence
of heel ulcers (13 vs. 0%) and one local
infection,further limiting the applicability
of ATL. In the case of temperature-guided
avoidance, adverse effects were not noted
and are unlikely to be signiﬁcant (perhaps
with the exception of false-positive read-
ings leading to unnecessary health care
visits).
Once a patient has lost SWM sensa-
tion, self-measurement of sole tempera-
ture, followed by off-loading when
temperature differences are detected, is
currentlytheonlyscientiﬁcallysupported
tool for the prediction and prevention of
diabetic foot ulcers in an insensate foot.
Although the application of this concept
for all patients with an insensate foot
needs to be evaluated, it has the potential
to reduce the risk of such patients pro-
gressing to ulcer development.
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